Ergoset oral bromocriptine D2 dopamine agonist: ERGO began enrollment in a double-blind U.S. Phase II/III trial in 400 obese patients. Patients will receive pla

The trial is intended to determine the best dose of Ergoset to use

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE